Project Selection

The intent of the Steering Committee is to identify projects that will be amenable to currently available technologies in cell therapy and to provide a framework for experimental development that allows pre-clinical observations to evolve into clinical trials. Once a project has been selected by the Steering Committee, the Translational Cell Therapy Lab at the CBR Institute for Biomedical Research (CBRI) and the Regulatory Core at the Dana Farber Cancer Institute (DFCI) Cell Manipulation Core Facility are responsible for identifying resource requirements such as support staff, equipment, and reagents relevant for each investigator. Pre-clinical studies are completed in the Translational Cell Therapy Lab and the Regulatory Core contributes to this process by providing expertise in developing clinical protocols that will be acceptable to the institutional and federal regulatory authorities, including the Food and Drug Administration. Thus, clinical investigators with no previous experience in cell therapy can be assisted by our team.

The CHCT also supports technical staff and post-doctoral fellows working with these investigators outside the Center. Hence, the Center has considerable flexibility in the way its resources are used.